The latest update is out from Exact Sciences (EXAS).
Exact Sciences Corporation is gearing up for growth and the introduction of innovative cancer tests, aligning its sales and marketing under the Screening and Precision Oncology teams to improve agility and customer service. Leaders Jake Orville and Brian Baranick will spearhead these teams, continuing their tenure from 2022, while the company bids farewell to departing Chief Commercial Officer Everett Cunningham. With confidence, Exact Sciences maintains its Q2 and full-year 2024 revenue forecasts, projecting up to $697 million and $2.85 billion respectively, alongside an adjusted EBITDA of $350 million.
See more insights into EXAS stock on TipRanks’ Stock Analysis page.
